A review on recipients of hematopoietic stem cell transplantation patients with COVID-19 infection.
Kamal Kant SahuAhmad Daniyal SiddiquiPublished in: Therapeutic advances in infectious disease (2021)
For the last few months, various geographical regions and health sectors have been facing challenges posed by the current COVID-19 pandemic. COVID-19 has led to significant disruption in the normal functioning of potentially life-saving therapies of hematopoietic cell transplant and chimeric antigen receptor therapy. As transplant physicians are gaining more information and experience regarding the undertaking of these complex procedures during the ongoing COVID-19 pandemic, we believe it is important to discuss the challenges faced, prognostic risk factors, and outcomes of COVID-19 in post-hematopoietic stem cell transplantation patients based on the available real-world data.
Keyphrases
- coronavirus disease
- sars cov
- risk factors
- end stage renal disease
- acute myeloid leukemia
- primary care
- ejection fraction
- healthcare
- newly diagnosed
- chronic kidney disease
- public health
- peritoneal dialysis
- mental health
- cell therapy
- stem cells
- machine learning
- electronic health record
- big data
- insulin resistance
- deep learning
- adipose tissue
- replacement therapy
- human health
- weight loss